China's medical products administrator approved Innovent Biologics' (HKG:1801) limertinib for a mutation of locally advanced or metastatic non-small cell lung cancer, according to a Friday filing with the Hong Kong Exchange.

The drug is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

It is indicated for the EGFR T790M mutation, which is the most common mutation and affects up to 50% of Asian patients of the disease, the filing said.

Shares rose 3% during Friday's late morning trading.